Primary Safety Objective:
To evaluate the safety and tolerability of IM156 with Gem+NP in patients with metastatic PDAC
Exploratory Efficacy Objective:
To evaluate the efficacy of IM156 with Gem+NP in patients with metastatic PDAC
Exploratory Biomarker Objective:
To identify biomarkers that are predictive of response to IM156 (i.e., predictive biomarkers), are associated with progression to a more severe disease state (i.e., prognostic biomarkers), are associated with resistance to IM156, are associated with susceptibility to developing adverse events, can provide evidence of study treatment activity, or can increase the knowledge and understanding of disease biology.
Source: View full study details on ClinicalTrials.gov
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. By listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
